Lieu, Hsiao D.

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

Harrison, S. A., Neff, G., Guy, C. D., Bashir, M. R., Paredes, A. H., Frias, J. P., Younes, Z., Trotter, J. F., Gunn, N. T., Moussa, S. E., et al. (2021) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 280

The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH

Loomba, R., Ling, L., Dinh, D. M., DePaoli, A. M., Lieu, H. D., Harrison, S. A., & Sanyal, A. J. (2021) · Hepatology

Gut microbiota and healthLiver Disease Diagnosis and Treatment

Cited by 88

Interaction of Caffeine With Regadenoson-Induced Hyperemic Myocardial Blood Flow as Measured by Positron Emission Tomography

Gaemperli, O., Schepis, T., Koepfli, P., Siegrist, P. T., Fleischman, S., Nguyen, P., Olmsted, A., Wang, W., Lieu, H., & Kaufmann, P. A. (2008) · Journal of the American College of Cardiology

Cardiac Imaging and DiagnosticsAdenosine and Purinergic Signaling

Cited by 52

Genetic control of autoimmune myocarditis mediated by myosin-specific antibodies

Kuan, A. P., Chamberlain, W., Malkiel, S., Lieu, H. D., Factor, S. M., Diamond, B., & Kotzin, B. L. (1999) · Immunogenetics

Viral Infections and Immunology ResearchSystemic Lupus Erythematosus Research

Cited by 38

Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis

Harrison, S. A., Neff, G., Guy, C., Bashir, M., Paredes, A., Frias, J., Younes, Z. H., Trotter, J. F., Gunn, N. T., Moussa, S., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 1